Lv1
28 积分 2025-07-23 加入
Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1个月前
已完结
Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management
2个月前
已完结
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study
6个月前
已完结
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial
6个月前
已完结
Role of the tumor microenvironment in CLL pathogenesis
11个月前
已完结
Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study
1年前
已完结
Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features
1年前
已完结
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement
1年前
已完结
REPORT OF CONSENSUS PANEL 2 FROM THE 12TH INTERNATIONAL WORKSHOP ON THE MANAGEMENT OF BING-NEEL SYNDROME IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA
1年前
已关闭
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
1年前
已完结